Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
About this study
The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint inhibitors (ICIs) therapy. The primary questions it aims to address are: 1. What is the real-world incidence of VTE/ATE in lung cancer patients receiving immune checkpoint inhibitors? 2. What are the risk factors and biomarkers for VTE/ATE in lung cancer patients receiving immune checkpoint inhibitors? 3. What is the impact of VTE/ATE on the prognosis of lung cancer patients receiving immune checkpoint inhibitors? Researchers will compare the characteristics and biomarkers of patients with and without ICI-associated VTE/ATE to identify novel specific biomarkers for thrombotic events. Furthermore, they will construct a risk assessment model for thrombotic events to provide guidance for precision prevention and treatment in clinical practice.
- Condition
- Lung Cancer, Venous Thromboembolism, Arterial Thromboembolism, Immune Checkpoint Inhibitors (ICIs)
- Sponsor
- Beijing Chao Yang Hospital
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 18 years
- Study condition: Lung Cancer, Venous Thromboembolism, Arterial Thromboembolism, Immune Checkpoint Inhibitors (ICIs)
- Age ≥18 years
- Histopathologically confirmed lung cancer diagnosis at enrollment
- Received at least one dose of a China-approved lung cancer immune checkpoint inhibitor
- Signed informed consent form
Exclusion 4
- Presence of two or more primary cancers
- Missing data for key variables
- Inability to comply with follow-up requirements
- Presence of VTE/ATE at the time of ICI initiation
Where
5 sites, 5 recruiting
Beijing Chaoyang Hospital, Capital Medical University
Beijing, China
Beijing Luhe Hospital, Capital Medical University
Beijing, China
China-japan Friendship Hospital
Beijing, China
The Fourth Hospital of Inner Mongolia Autonomous Region
Hohhot, Inner Mongolia, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Contact
-
Yuhui Zhang
86+13520108369 zhangyhcy@163.com
Potential match only. Final eligibility is determined by the study team.